Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cortexyme Inc (NQ: CRTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cortexyme Inc

< Previous 1 2 3 4 5 Next >
Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression
From Cortexyme, Inc.
Via Business Wire
Why This Alzheimer's Study Missed, But That's Not Necessarily A Bad Thing For Cortexyme
Cortexyme said Tuesday its experimental Alzheimer's drug might work in some patients. 
Via Investor's Business Daily
Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market
Cortexyme is testing a twice-day pill to treat Alzheimer's disease. 
Via Investor's Business Daily
Cramer Likes Azek And SoFi, But Said Owning This Stock Could Be Dreadful
On CNBC's "Mad Money Light... 
Via Benzinga
Before The Bubble Bursts
Maybe some good can come out of the market bubble -- for Alzheimer's patients, and for investors in Cortexyme. 
Via Talk Markets
Analyzing Cortexyme's Unusual Options Activity
On Monday, shares of Cortexyme (NASDAQ:CRTX) saw unusual ... 
Via Benzinga
51 Biggest Movers From Friday
Gainers LM Funding America, Inc. (NASDAQ: LMFA) shares jumped 38.1% to close at $4.75 on Friday after declining around 15% on Thursday. The company recently announced it... 
Via Benzinga
Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021
From Cortexyme, Inc.
Via Business Wire
Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588
From Cortexyme, Inc.
Via Business Wire
Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th
From Cortexyme, Inc.
Via Business Wire
10 Biggest Price Target Changes For Thursday
Keybanc raised the price target for Intuit Inc. (NASDAQ: 
Via Benzinga
Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit
From Cortexyme, Inc.
Via Business Wire
Cortexyme to Present at Annual Biomarkers for Alzheimer’s Disease Summit
From Cortexyme, Inc.
Via Business Wire
Cortexyme: Shifting The Odds In Your Favor So Your Best Case Outcome Is Three Times Higher Than Your Worst Case
Screen capture via Cortexyme animation. A Bigger Bubble Than The Late '90s Phoenix Capital Research offered an interesting comparison of the current stock market to that... 
Via Benzinga
The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small-... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers CohBar (NASDAQ:CWBR) shares incr... 
Via Benzinga
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
85 Biggest Movers From Yesterday
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX... 
Via Benzinga
Stocks That Hit 52-Week Highs On Tuesday
Before 10 a.m. ET on Tuesday, 100 stocks hit new 52-week highs. Things to Consider: The largest company by market cap to break to a new 52-week high was Pfizer (... 
Via Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures COVID-19
68 Biggest Movers From Yesterday
Gainers Golden Nugget Online Gaming, Inc. (NASDAQ: GNOG) shares climbed 50.8% to close at $18.50 on Monday after the company and DraftKings announced they entered into a... 
Via Benzinga
Mid-Afternoon Market Update: Aterian Falls After Q2 Results; Select Interior Concepts Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.17% to 35,150.02 while the NASDAQ rose 0.26% to 14,874.23. The S&P also rose, gaining 0.01% to 4,436.62. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers SCWorx (NASDAQ:WORX) shares moved upwards by 33.66% to $4.3 during Monday's regular session. As of 12:30 EST, this security is trading at a volume of 87.6... 
Via Benzinga
Mid-Day Market Update: Crude Oil Down 2.5%; Golden Nugget Online Gaming Shares Jump
Midway through trading Monday, the Dow traded down 0.23% to 35,126.98 while the NASDAQ rose 0.20% to 14,866.01. The S&P also fell, dropping 0.08% to 4,432.96. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Cortexyme Provides Business Update and Reports Second Quarter 2021 Results
From Cortexyme, Inc.
Via Business Wire
Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th
From Cortexyme, Inc.
Via Business Wire
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021
From Cortexyme, Inc.
Via Business Wire
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.